Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO

Abbas Kazimi has been appointed as the new Chief Executive Officer of Nimbus Therapeutics, effective immediately14.

Kazimi succeeds Jeb Keiper, who has stepped down from the position as part of a planned transition after serving as CEO for over 6 years14.

Kazimi joined Nimbus in 2014 and has served as Chief Business Officer since 20201.

During his tenure, Kazimi helped drive key transactions resulting in over $7 billion in upfront and milestone capital from pharmaceutical partners1.

Nimbus Therapeutics is a clinical-stage biotechnology company focused on structure-based drug discovery and development1.

The company's pipeline includes promising programs like WRN and SIK inhibitors, as well as an ongoing collaboration with Lilly1.

Nimbus utilizes a unique computational drug discovery engine to develop novel small molecule medicines1.

The leadership change comes at a pivotal time in the company's evolution, as it continues to advance its pipeline and strengthen its position in the industry14.

Sources:

1. https://www.businesswire.com/news/home/20250307658905/en/Nimbus-Therapeutics-Appoints-Abbas-Kazimi-as-Chief-Executive-Officer

4. https://endpts.com/jeb-keiper-steps-down-from-nimbus-ceo-post-business-chief-to-take-over/